Brief: Cytokinetics Announces Nmpa Approval Of Myqorzo® In China
17/12/2025 12:47
Dec 17 (Reuters) - Cytokinetics Inc CYTK.O: CYTOKINETICS ANNOUNCES NMPA APPROVAL OF MYQORZO® (AFICAMTEN) IN CHINA FOR PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY CYTOKINETICS INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM SANOFI CYTOKINETICS INC - ELIGIBLE FOR UP TO $142.5 MILLION IN MILESTONE PAYMENTS CYTOKINETICS INC - FDA REVIEWING NDA FOR AFICAMTEN WITH PDUFA DATE DECEMBER 26, 2025 Source text: ID:nGNX8mZ7C9 Further company coverage: CYTK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech